Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|March 2, 2014
- Pharmaceutical Technology-03-02-2014
- Volume 38
- Issue 3
7900 ICP-MS Increases Efficiency
7900 ICP-MS Increases Efficiency
The 7900 ICP-MS from Agilent Technolgies is a redesign of the 7700 Series. The instruments high-matrix technology allows laboratories to measure samples containing up to 25% total dissolved solids. This is 10 times higher than the current benchmark held by the 7700 ICP-MS, according to the company. The 7900’s new interface design, expansion-stage vacuum system, and orthogonal detector system (ODS) reduce background and improve sensitivity, improving signal to noise for 10-fold lower detection limits, according to the company. The patented ODS technology delivers up to 11 orders of magnitude dynamic range, from sub-ppt to percent-level concentrations, which enables users to measure trace elements and majors in the same run. In addition, the redesigned MassHunter software features a simpler user interface along with increased method automation capabilities.
Articles in this issue
over 12 years ago
Under New Ownershipover 12 years ago
Current issues with nanomedicinesover 12 years ago
Optimizing Solid Dosage Manufacturingover 12 years ago
European Union Packaging Safety Features Come into Effectover 12 years ago
Comparing Drug Layering and Direct Pelletization Processesover 12 years ago
Regulators Get Tough on Corruption in Chinaover 12 years ago
Best Practices in Adopting Single-Use Systemsover 12 years ago
Manufacturers Struggle with Breakthrough Drug Developmentover 12 years ago
Trends and Best Practices in Visual InspectionRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.